Axio Biosolutions is a medtech company focused on developing active medical products using novel biomaterials for advanced surgical and woundcare.
Axio Biosolutions uses innovative medical technology to create breakthrough products for management of trauma, surgical and chronic wounds, and save people's lives. Its flagship patented product, Axiostat, is India's first USFDA cleared woundcare product that controls moderate to severe bleeding within minutes.
Axio's platform is based on novel active biomaterials and has been used by the military and hospitals in more than 15 countries.
ONI Impact Thesis
By innovating to create an affordable range of advanced wound care and hemostatic products, Axio is helping advance the use of newer technologies in these healthcare segments in India and other emerging markets. Its products are providing patients – including those from India’s Next Half Billion – with a high-quality affordable alternative to both traditional, less efficient products (e.g. gauze, plasters, wadding) and more advanced, expensive products (e.g. foam dressings, hydrogels, sealants).